Dr. John Cush RheumNow
3 years 11 months ago
#ACR22- SpA Part1
-AI Future of Sacroiliitis Assessment AI in Detecting Sacroiliitis
-AxSpA: gender differences
-Can we alter neonatal gut microbiome to prevent SpA?
-Comorbidities in AxSpA
-Do Disease Activity Measures Really Capture AS in Women?
https://t.co/sFIZz7pKSF https://t.co/CAh5TZ4FEX
Dr. John Cush RheumNow
3 years 11 months ago
PreRA to Treat or Not!
Dr. Janet Pope ( @Janetbirdope ) weighs in. #ACR22
https://t.co/778jWLizeW https://t.co/ZHIQTuYyyg
Dr. John Cush RheumNow
3 years 11 months ago
Prescribing Methotrexate in Post-Roe Era
Dr. Cassy Sims ( @DrCassySims) reports live from #ACR22.
L09: Impact on Access to Methotrexate in the Post-Roe Era
https://t.co/GwgSqBj5EX https://t.co/WzFGnJyIf3
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
How women can reduce the risk of hip fracture?
Dr. John Cush RheumNow
3 years 11 months ago
Is exercise the missing medicine in lupus?
Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical Inactivity is Associated with Increased Expression of T cell inflammatory genes in Systemic Lupus.”
https://t.co/LomZ8U8pzj https://t.co/PEZHypeasB
Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the International Myositis Assessment and Clinical Studies Group (IMACS) steering committee.
Dr. John Cush RheumNow
3 years 11 months ago
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at #ACR22 Convergence.
https://t.co/nrsH7yB7wu https://t.co/TngS4Kk6YK
Dr. John Cush RheumNow
3 years 11 months ago
Artificial Intelligence in Detecting Sacroiliitis
Dr. Akhil Sood ( @AkhilSoodMD) discusses Abstract 0383 at #ACR22.
https://t.co/U52eAFOePr https://t.co/8WcecoF5Sr
Dr. John Cush RheumNow
3 years 11 months ago
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/HrC1GLZQRR https://t.co/yiHsxhpiWe
Dr. John Cush RheumNow
3 years 11 months ago
TIME Mag - "Why Masks Still Matter". 1) COVID is still out there; 2) Influenza on the rise. Authors write "With limited yet mixed data, we would be wise to ...err on the side of masking in high risk, indoor crowded public settings..." https://t.co/l8jiTwAdZz https://t.co/0QUKJDOhjs
